Valuation Matrix triangulates a stock’s fair value across five independent methods, plus a reverse DCF insight. Each method captures a different dimension of value; the weighted verdict answers "what is this worth today". Reverse DCF flips the question to "what growth rate is the market already pricing in" — so you see both the fair value and the expectations embedded in the quote.
Updated—
Built-in skill
Driven
Built-in skill
Five years of projected free cash flows discounted at the company's WACC, plus a terminal value at 2.5% perpetuity growth. Bear / base / bull scenarios are computed simultaneously, so the output is a range anchored in cash-flow economics rather than a single point estimate.
Forward P/E using analyst consensus EPS, applied against bear / base / bull sector multiple ranges. Ranges are calibrated by market — the US baseline, HK discount, and A-share premium in Consumer / Healthcare all differ meaningfully — and auto-expand when the stock's actual multiple sits outside the reference range.
Capital-structure-neutral valuation of the operating business. Most informative when comparing companies with different debt loads or in capital-intensive sectors where earnings are distorted by depreciation policy — it strips leverage and accounting differences out of the comparison.
Cash-flow yield benchmarked against sector-specific reference ranges. Grounds the valuation in cash actually delivered to shareholders rather than reported earnings — the number that matters for dividends, buybacks, and deleveraging capacity, and the hardest one to manufacture accounting-wise.
Sell-side 12-month price-target triangulation — low / median / high. A check against the community of analysts covering the name, intentionally weighted light so it informs rather than drives the verdict.
Solves backwards from today's market cap for the implied FCF growth